The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use insulin.

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the FDA has cleared the next-generation ...

DexCom Inc. DXCM recently announced the direct connectivity of the Dexcom G7 Continuous Glucose Monitoring (CGM) system with the Apple Watch. This added feature is now available to users in the United ...

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...

DexCom Inc. DXCM stock is trading higher on Monday after the diabetes management company reported positive results from its ...

DexCom reported that CONNECT data showed G7 improved HbA1c and time in range in Type 2 diabetes. DexCom's trial delivered Level A evidence for CGM use in adults with Type 2 diabetes not on insulin.

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...

DexCom trades at $74.63 per share and has stayed right on track with the overall market, gaining 8.3% over the last six months. At the same time, the S&P 500 has returned 6.9%.

DexCom (NASDAQ:DXCM) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings, ...

Insulet Corporation (PODD) and DexCom (DXCM) were among notable gainers in MedTech on Tuesday after Deutsche Bank initiated the diabetes device makers with Buy ratings despite their sharp sell-off in ...